Bicycle Therapeutics Past Earnings Performance
Past criteria checks 0/6
Bicycle Therapeutics's earnings have been declining at an average annual rate of -35.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 31.2% per year.
Key information
-35.1%
Earnings growth rate
-10.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 31.2% |
| Return on equity | -20.0% |
| Net Margin | -450.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern
Nov 07Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 03
Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 23Bicycle Therapeutics Is Looking Increasingly Attractive
Aug 20Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07Revenue & Expenses Breakdown
How Bicycle Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 37 | -166 | 65 | 0 |
| 30 Jun 24 | 40 | -165 | 62 | 0 |
| 31 Mar 24 | 42 | -168 | 62 | 0 |
| 31 Dec 23 | 27 | -181 | 60 | 0 |
| 30 Sep 23 | 25 | -162 | 59 | 0 |
| 30 Jun 23 | 23 | -140 | 52 | 0 |
| 31 Mar 23 | 15 | -124 | 48 | 0 |
| 31 Dec 22 | 14 | -113 | 50 | 0 |
| 30 Sep 22 | 15 | -101 | 50 | 0 |
| 30 Jun 22 | 16 | -87 | 48 | 0 |
| 31 Mar 22 | 14 | -78 | 42 | 0 |
| 31 Dec 21 | 12 | -67 | 32 | 0 |
| 30 Sep 21 | 12 | -66 | 35 | 0 |
| 30 Jun 21 | 11 | -62 | 34 | 0 |
| 31 Mar 21 | 11 | -56 | 32 | 0 |
| 31 Dec 20 | 10 | -51 | 29 | 0 |
| 30 Sep 20 | 12 | -38 | 22 | 0 |
| 30 Jun 20 | 9 | -37 | 19 | 0 |
| 31 Mar 20 | 9 | -35 | 16 | 0 |
| 31 Dec 19 | 14 | -31 | 15 | 0 |
| 30 Sep 19 | 10 | -33 | 13 | 0 |
| 30 Jun 19 | 11 | -31 | 11 | 0 |
| 31 Mar 19 | 11 | -26 | 10 | 0 |
| 31 Dec 18 | 7 | -22 | 8 | 0 |
| 30 Sep 18 | 7 | -21 | 9 | 0 |
| 31 Dec 17 | 2 | -16 | 6 | 0 |
Quality Earnings: BCYC is currently unprofitable.
Growing Profit Margin: BCYC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BCYC is unprofitable, and losses have increased over the past 5 years at a rate of 35.1% per year.
Accelerating Growth: Unable to compare BCYC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BCYC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: BCYC has a negative Return on Equity (-20.01%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 09:37 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bicycle Therapeutics plc is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Kalpit Patel | B. Riley Securities, Inc. |
| Arlinda Lee | Canaccord Genuity |